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ABSTRACT By performing homology modeling, molecular docking, and molecular dynamics simulations, we have developed
three-dimensional (3D) structural models of both dopamine transporter and dopamine transporter-dopamine complex in the
environment of lipid bilayer and solvent water. According to the simulated structure of dopamine transporter-dopamine complex,
dopamine was orientated in a hydrophobic pocket at the midpoint of the membrane. The modeled 3D structures provide some
detailed structural and mechanistic insights concerning how dopamine transporter (DAT) interacts with dopamine at atomic level,
extending ourmechanistic understanding of the dopamine reuptakewith the help of Na1 ions. The general features of themodeled
3Dstructures are consistentwith available experimental data. Basedon themodeled structures, our calculated binding free energy
(DGbind¼6.4 kcal/mol) for dopaminebindingwithDAT is also reasonably close to theexperimentally derivedDGbind valueof7.4
kcal/mol. Finally, a possible dopamine-entry pathway,which involves formation andbreakingof the salt bridgebetweenside chains
of Arg85 and Asp476, is proposed based on the results obtained from the modeling and molecular dynamics simulation. The new
structural and mechanistic insights obtained from this computational study are expected to stimulate future, further biochemical
and pharmacological studies on the detailed structures and mechanisms of DAT and other homologous transporters.
INTRODUCTION
Dopamine transporter (DAT) is an important protein for
movement and Parkinsonism. Its native substrate, dopamine,
is a vital neurotransmitter for locomotor control and reward
systems, including those lost or deranged in Parkinson’s
disease (1). DAT is also the primary target of cocaine.
Cocaine is the most reinforcing of all drugs of abuse (2,3,4).
Through binding with DAT, cocaine blocks the clearance
(reuptake) of dopamine from central nervous system synapses
and thereby prolongs dopaminergic neurotransmission in
brain areas associated with reward. There are millions of
individuals worldwide addicted to cocaine. Such a public
health crisis has carried a substantial burden to the society in
the form of increasing medical expenses, lost earnings, and
increased crimes associated with psychostimulant abuse.
There is no available medication approved by Food and Drug
Administration to be used against cocaine addiction (1,5). The
disastrous medical and social consequences of cocaine ad-
diction have made the development of an effective pharma-
cological treatment a high priority (6–13).
Physiologically, DAT spatially and temporally buffers
released dopamine at synaptic cleft, terminating dopaminer-
gic neurotransmission and reaccumulating dopamine into pre-
synaptic neurons. The transporting process can be roughly
modeled as involving several different DAT states: bound
state for dopamine and ions; intracellular unloading state of
dopamine and ions; and ﬁnally extracellularly facing state as
an unloaded carrier (14,15). Pharmacological studies have
shown that dopamine transporting by DAT is Na1/Cl-
dependent. The overall stoichiometry is likely as dopamine/
Na1/Cl¼ 1:2:1 (16,17). Site-directed mutagenesis has been
performed extensively on DAT to search for amino-acid
residues responsible for the Na1 action, dopamine binding,
and their coupling with the actions of cocaine (18–29). How-
ever, molecular mechanisms for these actions have appeared
as complex and bewildering. A knock-in mouse model with
functional DAT has been developed and found to be insen-
sitive to cocaine (5). Such progress is paving the way of fully
understanding the structure-function relationships of DAT
system. However, structural details about the interactions of
DAT with dopamine, cocaine, and its analogs remain to be
uncovered. These facts make highly desirable a study on how
the DAT interacts with its substrate.
DAT is a member of the neurotransmitter sodium sym-
porters (NSS) family, belonging to the ion-coupled secondary
transporters superfamily (STS) (30–34). The STS is known as
the largest superfamily of membrane proteins of transporters
with more than 1000 identiﬁed members to date (30). Driven
by a solute gradient, these proteins transport ions, drugs,
neurotransmitters, and other hydrophilic solutes. Some typ-
ical members of this superfamily have been structurally
characterized through x-ray crystallography and, therefore,
their possible transporting mechanisms have been explored.
For example, the Glycerol-3-phosphate transporter (GlpT)
(Protein Data Bank, i.e., PDB entry of 1PW4with a resolution
of 3.3 A˚) operates by a singly-binding site, alternating-access
mechanism (30). Another typical example is the Lactose
permease (LacY, PDB entry of 1PV7 with a resolution of 3.6
A˚) as a representative of Lactose subfamily (31). Besides the
protonated, inward-facing conformation of LacY with bound
substrate, the outward-facing conformation open to the
periplasmic side is considered to be required for the ﬁnal
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substrate transport across the membrane. Transporters in
NSS family usually use sodium and chloride electrochemical
gradients to catalyze the thermodynamically uphill move-
ments for a series of substrates such as serotonin and
dopamine (31,34). More recently, the x-ray crystal structure
for a bacterial homolog (LeuTAa) of NSS from Aquifex
aeolicus was determined in complex with substrate leucine
and two sodium ions (PDBentry of 2A65 at 1.65 A˚ resolution)
(34). This structure is viewed as an extracellularly faced state
with the bound substrate. The possible substrate-entry pathway
was proposed to be along transmembrane helices 1, 3, 6, and
8, starting from the extracellular end of these helices to the
substrate-binding site. LeuTAa shares similar topological
features with GlpT and LacY, i.e., 12 transmembrane
a-helices with intracellular localization of both N-terminal
and C-terminal, and a large internal substrate-binding cavity
on the midpoint of the membrane. However, LeuTAa is quite
different from GlpT and LacY (31,32,34). It bears a pseudo-
twofold helix packing axis between helices 1–5 and helices
6–10, whereas GlpT and LacY have such a twofold axis
between helices 1–6 and helices 7–12. The substrate-binding
site in LeuTAa is located among partially unwound trans-
membrane helices 1, 3, 6, and 8 with main-chain atoms and
helix dipoles playing a key role in the binding of substrate and
sodium ions (34). In GlpT and LacY, the hydrophilic cavity is
among helices 1, 4, 5, 7, and 11. These three typical
transporters with available x-ray crystal structures belong to
different families of transporter proteins. Some molecular
modeling has been performed on DAT, serotonin transporter
(SERT), and noradrenalin transporter (NET) (35,36) by using
Na1/H1 antiporter or LacY (31) as the template. Now it is
obvious that these templates in previous modeling studies are
not suitable for the homology modeling of any member of the
NSS family. Hence, the predicted atomic interactions are not
reliable. No experimental evidence has been reported to
support the previously reported models from any kind of
structural or biological studies. Therefore, the previously
reported structural models of DAT, SERT, and NET are not
good enough to be used for studyingmolecular interactions of
psychotropic drugs with these transporters. With similar
structural folding and physiological features as other NSS
family members, LeuTAa has been viewed as the most
reasonable template to study the substrate binding and
transporting mechanism for NSS transporters, especially for
dopamine transporter and serotonin transporter (5).
In this work, a new three-dimensional (3D) structural
model of DAT has been constructed through homology
modeling based on the most reasonable template, i.e., the
LeuTAa structure (34), and reﬁned by performing molecular
dynamics (MD) simulations in the environment of lipid
bilayer and solvent water. Based on the developed structural
model of DAT, the substrate-binding mode has been deter-
mined through further molecular docking, MD simulations,
and binding free energy calculations. Through MD simula-
tions on both theDATmodelwithout dopamine and theDAT-
dopamine binding complex, a possible substrate-entry path-
way has been proposed. The overall agreement between the
computational results and available experimental data (16,21,
25,26,28) demonstrates important structural features of DAT
and its binding with substrate, providing some valuable in-
sight into the molecular mechanism for DAT modulating
dopamine reuptake.
COMPUTATIONAL METHODS
Homology modeling and structural optimization of
DAT in a physiological environment
To understand how dopamine binds with DAT and further explore the
possible substrate-entry pathway, a 3D structural model of DAT was built
based on the x-ray crystal structure of LeuTAa (34) by using the Homology
module from the InsightII software (Ver. 2000, Accelrys, San Diego, CA).
The amino-acid sequence of human DAT was directly extracted from the
NCBI databank (access No.: Q01959). The sequence alignment was gen-
erated by using ClusterW with the Blosum scoring function (37,38). The
best alignment was selected according to both the alignment score and the
reciprocal positions of the conserved residues among the NSS family. These
include the NGGGF motif between transmembrane helix 1 and 2, and other
residues around the Na1 binding sites in DAT. The ﬁrst 55 residues at the
N-terminal and the last 32 residues at the C-terminal were omitted because of
no corresponding homolog sequence in the template. A piece of 25 residues
inside extracellular loop 2 was manually skipped under the template to get a
better alignment at the conserved positions of Pro176 and Glu215 of DAT
with the template and other members in the NSS family, including glycine
transporter and serotonin transporter. The sequence identity reached 20.4%
and the whole sequence homology became 42.0% for the ﬁnal alignment
(Fig. 1). The coordinates of the conserved regions were directly transformed
from the template structure (i.e., the x-ray crystal structure of LeuTAa (34)),
while the nonequivalent residues were mutated from the template to the
corresponding ones of DAT. The side chains of those nonconserved residues
were relaxed by using the Homology module of InsightII to remove the
possible steric overlap or hindrance with the neighboring conserved res-
idues. The conformation of the inserted 25 residues inside extracellular loop
2 was searched from the internal database of InsightII software and the best
ﬁt was selected from the generated 10 candidates.
To simulate the actual physiological environment, the initial DAT model
was inserted into a preequilibrated POPC lipid bilayer and then solvated by
two layers of water molecules at each side of lipid bilayer. The POPC bilayer
was generated by using the membrane plug-in of the VMD software (39) and
the initial size of the membrane was expanded to be large enough to en-
compass the target protein. The geometry of POPC molecule was optimized
by performing ab initio electronic structure calculation at the HF/6-31G*
level using Gaussian-03 program (40). The HF/6-31G* calculation was also
performed to determine the restrained electrostatic potential (RESP)-ﬁtted
charges for POPCmolecules. The similar RESP-ﬁtting calculations based on
the ﬁrst-principles electronic structure method were used in our previous
computational studies of other protein-ligand systems and led to satisfactory
binding structures (41–45). The relative orientation of DAT in the lipid
bilayer was determined by referring the similar orientation of the LeuTAa
structure (34), i.e., transmembrane helix 12 in parallel with the normal of the
membrane, the binding sites of two Na1 placed at the midpoint of the mem-
brane, and the two terminals (both N-terminal and C-terminal) intracellularly
located. When inserting, any POPC molecule was removed if it had .50%
of its nonhydrogen atoms within a distance of 2.5 A˚ to any nonhydrogen
atoms of DAT. The solvent layers were added by using the LEaP module of
AMBER8 program suite (46). The protein together with the lipid bilayer was
solvated in a rectangular box of TIP3P water molecules (47) with a min-
imum solute wall distance of 10 A˚. The redundant water molecules beyond
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the x,y boundary of the membrane were cut off to match the size of lipid
bilayer. Standard protonation states at physiological environment (pH;7.4)
were set to all ionizable residues of DAT, and the positions of protons were
properly set on Nd1 atom of His residues. Additional 4 Na1 were added in
the solvent as counterions to neutralize the whole system. The ﬁnal system
size was;126 A˚3 125 A˚3 118 A˚, composed of 154,114 atoms, including
351 POPC molecules and 32,390 water molecules.
After the whole system was set up, a series of energy minimizations (or
geometric optimizations) were carried out by using the Sander module of
AMBER8 program suite (46) with a nonbonded cutoff of 12 A˚ and a
conjugate gradient energy-minimization method. The ﬁrst 2000 steps of the
energy minimization was done for the backbone of DAT while the side
chains were ﬁxed, and then the next 20,000 steps for the side-chain atoms
with the backbone ﬁxed. To get the solute (DAT) better solvated, the sub-
sequent energy minimization and short-time MD simulations were performed
on the environment (i.e., the lipid molecules, water molecules, and the
counterions). After 50,000 steps of energy minimization on the environment,
80-ps MD simulations were performed on water molecules with NTV
ensemble at T ¼ 300 K. The environment was energy-minimized again for
20,000 steps followed by a 30-ps MD simulation on the lipid molecules.
After these MD simulations, the environment and side chains of DAT
were energy-minimized for 25,000 steps. Finally, the system was energy-
minimized for 6000 steps for all atoms, and a convergence criterion of 0.001
kcal mol1 A˚1 was achieved.
Molecular docking and binding free
energy calculation
Based on the structural model of DAT obtained in this study, the binding
mode of dopamine with DAT was explored through molecular docking by
using the AutoDock 3.0.5 program and the DOCK 5.4 program (48,49). The
two different docking programs were used for the same system for the
purpose of increasing the number of possible candidates of the binding
complex. The atomic charges of the protonated dopamine were also deter-
mined as the RESP charges determined by using the standard RESP pro-
cedure implemented in the Antechamber module of the AMBER8 program
(46) after the electronic structure and electrostatic potential calculations at
the HF/6-31G*. During the AutoDock docking process, a conformational
search was performed using the Solis and Wets local search method (50),
and the Lamarckian genetic algorithm (48) was applied to deal with the
DAT-dopamine interactions. Among a series of docking parameters, the grid
size was set to be 60 3 60 3 60 and the grid space was the default value of
0.375 A˚. Similar grid size was used in the DOCK 5.0 docking operation, and
the protonated dopamine molecule was ﬂexibly treated by using the anchor-
and-grow algorithm (49). The possible binding site in DAT was ﬁrst roughly
deﬁned as a similar site in LeuTAa structure (34), i.e., the cavity around
transmembrane helices 1, 3, 6, and 8. The binding site was then hunted by
changing the center and the size of the docking grid. All the complex
candidates were evaluated and ranked in terms of binding energy by using
the standard energy score function implemented in the docking programs
and the geometric matching quality.
As both the docking programs cannot consider the structural ﬂexibility of
the binding site during the docking process, further energy minimizations on
those initially selected 20 complexes were performed in a similar way as
described above, i.e., 10,000 steps with the ﬁxed backbone of DAT, and then
15,000 steps or the convergence criteria 0.001 kcal mol1 A˚1 reached for
all of the atoms. The molecular mechanics (MM) method-based interaction
energy for each of these energy-minimized 20 candidates was calculated
according to the following equations,
DEMM ¼ Ecomplex  EDAT  EDA; (1)
DEMM ¼ DEele1DEvdw; (2)
where DEMM is the binding energy contributed from electrostatic and van
der Waals interactions; Ecomplex, EDAT, and EDA were the energies of the
complex, free DAT, and free dopamine, respectively. All these terms were
calculated with the Sander module of the AMBER8 program (46). By this
way of ranking and checking of geometric match quality, two complex
structures were selected as the ﬁnal candidates, and then subjected to more
accurate binding free energy calculations by using the molecular mechanics-
Poisson-Boltzmann surface area (MM-PBSA) method (51).
In the MM-PBSA calculations, the free energy of dopamine binding,
DGbind, is calculated from the difference between the free energies of the
complex (Gcomplex), the free DAT (GDAT), and free dopamine (GDA) as
Eq. 3:
FIGURE 1 Sequence alignment of human DAT with the bacterial homolog of Na1/Cl-dependent neurotransmitter transporters (LeuTAa) by manual
adjustment. Twelve helices are labeled above the sequence, and strictly conserved residues among the NSS family are shown in bold.
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DGbind ¼ Gcomplex  ðGDAT1GDAÞ: (3)
The DGbind was evaluated as a sum of the changes in the MM gas-phase
binding energy (DEbind), solvation free energy (DGsolv), and entropy con-
tribution (TDS),
DGbind ¼ DEbind  TDS; (4)
DEbind ¼ DEMM1DGsolv; (5)
DGsolv ¼ DGPB1DGnp; (6)
DGnp ¼ gSASA: (7)
Electrostatic solvation free energy was calculated by the ﬁnite-difference
solution to the Poisson-Boltzmann (PB) equation (DGPB) as implemented in
the Delphi program (52,53). The dielectric constants used were 1 for the
solute and 78.5 for the solvent. The SASA was calculated by the default
surface area calculation program in the MM-PBSA module of AMBER8
program (46) with the default g ¼ 0.0072 kcal A˚2. In the MM-PBSA
calculations, the lipid molecules were treated as part of the solute because
DAT is a membrane protein. Keeping lipid molecules as part of the ‘‘solute’’
are helpful to reduce some possible systematic errors, especially for the
calculation of DGPB. To avoid the insufﬁcient accuracy of solvation energy
calculation for metal ions by Delphi program, the two bound Na1 ions were
removed only when calculating DGPB. The entropy contribution, TDS, to
the binding free energy was calculated at T ¼ 300 K by using the Nmode
module of the AMBER8 program (46), which is based on a combination of
the standard classical statistical formulas and normal mode analysis (54,55).
After the calculation of binding free energy, one of the two candidate
structures was selected as the ﬁnal DAT-dopamine complex based on its
much lower binding free energy and higher quality of structural matching.
Molecular dynamics simulations
To explore the possible substrate-entry pathway, MD simulations were
performed on the aforementioned DAT system by using the Sander module
of AMBER8 (46). MD simulations were performed also for the purpose of
making the extracellular loop 2 more reasonably folded after a sequence of
25 residues was inserted during the modeling of DAT structure. The whole
system was gradually heated to 300 K by weak-coupling method (56,57) and
equilibrated for;49 ps. Throughout the MD simulations, a 12 A˚ nonbonded
interaction cutoff was used and the nonbonded list was updated every 1000
steps. The particle-mesh Ewald method (58,59) was applied to treat long-
range electrostatic interactions. The lengths of bonds involving hydrogen
atoms were ﬁxed with the SHAKE algorithm (60), enabling the use of a 2-fs
time step to numerically integrate the equations of motion. Finally, the pro-
duction MDwas kept running;2.167 ns with a periodic boundary condition
in the NTP ensemble at T¼ 300 K with Berendsen temperature coupling and
at P ¼ 1 atm with anisotropic molecule-based scaling (56,57).
Similar MD simulations were also performed for 2.476 ns on the
constructed DAT-dopamine complex for the purpose of further relaxation of
the structure.
Most of the MD simulations were performed on the HP supercomputers
(Superdome SDX and Linux cluster XC) at University of Kentucky Center
for Computational Sciences. The other computations were carried out on
SGI Fuel workstations and a 34-processor IBM x335 Linux cluster in our
own lab.
RESULTS AND DISCUSSION
Structural model of DAT
The amino-acid sequence alignment between human DAT
and LeuTAa (Fig. 1) shows that 12 regions with high homo-
logy can be assigned to 12 a-helices. The assembly of these
helices in a biological environment (Fig. 2 A) is structurally
organized similar to the template LeuTAa (34). The whole
model appeared to be a shallow glasslike shape opening to-
ward the extracellular side and a pseudo-twofold axis between
helices 1–5 and helices 6–10. The energy-minimized DAT
structure (Fig. 2) has a root-mean-square deviation (RMSD)
of 0.13 A˚ for Ca atoms and 0.69 A˚ for all heavy atoms from
the initial structural model. Compared with the template
LeuTAa structure (34), the RMSD for Ca atoms of 12 trans-
membrane helices was only 0.52 A˚. These small structural
deviations suggest a high ﬁdelity for the structure prediction
of DAT. Like other bacterial homologs in the same family
(61), the ﬁrst 10 helices of DAT should act as the essential
core structure for Na1/Cl-dependent transporting. With
FIGURE 2 Initial structural model of human DAT in the physiological environment used for MD simulations. (A) DAT protein is represented as ribbon in
red, lipid molecules in gray, and water molecules in green. Labeled also are the system sizes along x, y, and z axes. (B) Top view of DAT protein itself shown as
ribbon in red, and Na1 ions as CPK in magenta. The Na1 ions, extracellular loop 2 (EL2), transmembrane helix 12 (TM12), and Nter are labeled. (C) Side view
of DAT protein.
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inverted V-shape, helices 9 and 10 hold helices 3 and 8 like a
pincer. By ﬂanking the outer surfaces of helices 9 and 10,
helix 12 protrudes the deepest into the intracellular side.
Together with helix 9, helix 12 is situated probably at the
interface of DAT dimer or other possible oligomers such as
the tetramer (62,63).
Our MD-simulated DAT model is considerably different
from the previously reported DATmodels (35,36). Themajor
difference exists not only in the starting position and the
length of each helix, but also in the assembly of 12 trans-
membrane helices. Furthermore, the second substrate (i.e., the
two Na1 ions) (31) was not considered in the previous DAT
models. These differences between the previous models and
our current model are mainly due to the fact that the more
reasonable template (34) was used in our DAT structure
prediction. As noted above, the template (i.e., the structure of
LeuTAa) used to build our model is in the same NSS family to
which DAT belongs, whereas the previous models (35,36)
were constructed from different templates, one from the Na1/
H1 antiporter, and another from Lactose permease (31). The
Na1/H1 antiporter and Lactose permease belong to different
families of the ion-coupled secondary transporters superfam-
ily; neither of these two templates shares the same family with
DAT. In addition, the effects of the lipid bilayer and solvent
molecules on theDAT structurewere also accounted for in the
structural optimization process (Fig. 2 A). The energy min-
imization on the system including the lipid bilayer and solvent
molecules helped to improve the quality of interhelical pack-
ing and the helix-bilayer packing. The obtained model struc-
ture (Fig. 2) should be more reasonable than the previous
models obtained from the in-vacuum modeling (35,36) In
general, the existence of the membrane bilayer and solvent
molecules is crucial for maintaining the proper folding of
membrane proteins and their reasonable conformational
changes necessary for the normal protein functions (64).
Based on the Ca RMSD changes during the MD simula-
tion (black curve in Fig. 3 A), one can see that the optimized
DAT structure became further relaxed after ;0.4 ns of the
signiﬁcant structural perturbation. Such structural change
during 0;0.4 ns may be attributed to the dynamic packing
effect by lipid molecules on the relative assembly of DAT
helices. After ;0.4 ns, the helix assembly of DAT became
relatively stable as the Ca RMSD curve became quite ﬂat.
It is interesting to track the distance change between the
positively charged side-chain atoms of Arg85 from helix 1 and
the negatively charged side-chain atoms of Asp476 from helix
8 during theMDsimulation (black curve in Fig. 3B). As noted
in the x-ray structure of LeuTAa (34), these two residues may
also form an ion-pair in DATwithout a substrate, and this ion-
pair was supposed to be the major obstacle when the substrate
is on the way to enter the binding pocket. There were
hydrogen-bonding and strong electrostatic interactions be-
tween Arg85 andAsp476 in the starting DAT structure used for
the MD simulation. During the MD simulation, the minimum
distance between the side chains of these two residues be-
camemuch larger and there was a very large ﬂuctuation of the
distance, indicating that the Arg85-Asp476 pair (salt bridge)
was seldomly formed during the MD simulation and easy to
be separated (Fig. 3 B).
The Na1 ions were bound on the midpoint of the mem-
brane, roughly around the unwound regions of helices 1 and 6
(Fig. 2,B andC). Themajor role of these twoNa1 ionsmay be
considered to stabilize the DAT core structure and the
unwound helices 1 and 6. The two Na1 ions may also help to
turn the DAT to externally facing form, thus allowing the
access of the substrate to its binding site (16,17,20). In our
starting structure of DAT used in the MD simulation, the ﬁrst
Na1 (denoted byNa1 in Fig. 2,B andC) was coordinatedwith
the carbonyl oxygen of Ala77 (helix 1), side-chain carbonyl
oxygen of Asn82 (helix 1), backbone carbonyl oxygen and
side-chain hydroxyl oxygen of Ser321 (helix 6), and carbonyl
oxygen of Asn353 (helix 7). In LeuTAa (34), the sixth co-
ordination of the corresponding Na1 was from the carboxyl
oxygen of the substrate. Correspondingly, the space around
the sixth coordination of Na1 in DAT was squeezed by the
surrounding backbone atoms. Tracking the coordination
information in the MD trajectory, we found that the most
conserved residues Ala77, Asn82, and Asn353 (Figs. 1 and 4 A)
were always the ligands of Na1 (Table 1). Ser321 coordinated
Na1 through its backbone carbonyl oxygen, but the coordi-
nation of its side-chain hydroxyl oxygen was replaced by the
FIGURE 3 Plots of the Ca RMSD and key distances in the simulated
DAT and DAT-dopamine structures versus the simulation time (nanosec-
onds) during the MD simulations. (A) The DAT Ca RMSD, the Ca RMSD
of the DAT-dopamine complex, and the RMSD of dopamine (DA) in the
complex. (B) The minimum-distance changes between the positively
charged side-chain atoms (NE, NH1, and NH2) of Arg85 and the negatively
charged side-chain atoms (OD1 and OD2) of Asp476 in both the DAT and
DAT-dopamine complex.
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side-chain hydroxyl oxygen of Ser357. Further coordina-
tion by the backbone carboxyl oxygen of Phe76 made Na1
saturated to the typical hexacoordination and thus Na1 was
stabilized in its binding site. During the MD simulation, Na1
had a fraction of 0.580 for hexacoordination and a fraction of
0.397 for pentacoordination. As shown in Fig. 4 A, for a
typical DAT structure at 1.50-ns snapshot of the MD tra-
jectory, most of the coordinating atoms interact with Na1
FIGURE 4 Representative local structures of DAT
surrounding the Na1 ions (i.e., Na1 and Na2) captured at
1.50 ns snapshot of the MD simulations on DAT (A for
Na1 and B for Na2) and DAT-dopamine complex (C for
Na1 and D for Na2). In all cases, Na1 ions are shown in
CPK style. The coordinating residues are shown in stick,
and the protein in ribbon, representation. The coordinating
distances are labeled.
TABLE 1 Coordination details for the Na1 ions during the MD simulations for both the DAT model and its complex structure
with dopamine
DAT DAT-dopamine complex
Ions Residue Atom Fraction Residue Atom Fraction
Na1 Phe76 O¼C 0.735 Ala77 O¼C 1.000
Ala77 O¼C 0.988 Asp79 OD2 1.000
Asn82 OD1 0.998 Asn82 OD1 1.000
Ser321 O¼C 0.991 Phe320 O¼C 0.995
Asn353 O¼C 1.000 Ser321 O¼C 0.944
Ser357 OG 0.965
Ser321 OG 0.091
Coordination No. and its fraction
5: 0.397
6: 0.580
Coordination No. and its fraction
4: 0.006
5: 0.963
6: 0.030
Na2 Gly75 O¼C 0.965 Gly75 O¼C 1.000
Asp79 OD1 0.948 Val78 O¼C 1.000
Leu418 O¼C 0.911 Leu418 O¼C 0.994
Asp421 OD1 1.000 Asp421 OD1 1.000
Asp421 OD2 0.963 Asp421 OD2 1.000
Ser422 OG 0.741
Val78 O¼C 0.032
Coordination No. and its fraction 5: 0.200
6: 0.780
Coordination No. and its fraction 4: 0.045
5: 0.949
A distance cutoff of 3 A˚ was used for the coordination criterion, and the fraction was calculated as the ratio of the number of snapshots with the coordination
to the total number of snapshots taken from the stable MD trajectory. The fraction of each coordination number (4, 5, or 6) was calculated similarly.
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within an internuclear distance of 2.5 A˚, except the backbone
carbonyl oxygen of Ser321 with a distance of 2.64 A˚. The
details of the coordination for Na1 revealed in this MD sim-
ulation on DAT structure are all consistent with the obser-
vations from experimental studies for the existence of Na1
and its couplingwith the substrate binding inDAT and SERT,
suggesting a general structural feature around Na1 for NSS
transporters (16,17,34).
The ligands of the second Na1 (denoted by Na2 in Fig. 2, B
and C, and Fig. 4 B) in the starting DAT structure used in the
MD simulation were mostly the backbone carbonyl oxygen
atoms. These ligands were the carbonyl oxygen atoms of
Gly75 (helix 1), Val78 (helix 1), and Leu418 (helix 8), the side
chain OD1 of Asp79 (helix 1), and the side-chain atoms OD1
andOD2 ofAsp421 (helix 8). As shown in Table 1 and Fig. 4B,
the most conserved residues Gly75 and Asp79 and the con-
servatively substituted Leu418 had very high fractions of the
coordination toNa2with short coordinating distances. Asp421
always coordinated to Na2 through the negatively charged
side-chain atoms OD1 and OD2, which was the main source
of electrostatic interactions. The coordination to Na2 by the
side-chain hydroxyl oxygen of Ser422 was sometimes
replaced by the backbone carbonyl oxygen of Val78, which
only had a very small fraction of the coordination. The frac-
tion of hexacoordination for Na2 was larger than that for Na1
by ;0.200, as seen in Table 1.
Complex model of DAT binding with dopamine
The dopamine-binding site in DAT was made by unwound
regions of helices 1 and 6 and helices 3 and 8, which was
close to the sites of Na1-binding, as seen in Fig. 5 A. In a
typical structure of the MD-simulated DAT-dopamine com-
plex at the 1.50-ns snapshot of the MD trajectory, dopamine
was located in a totally dehydrated pocket (Fig. 5 B). The
cationic head of dopamine was partially neutralized by the
helix dipoles at the unwound regions of helices 1 and 6, and
the negatively charged side chain of Asp79 from helix 1.
The dynamic behavior of the DAT-dopamine complex has
been monitored by the Ca RMSD changes (Fig. 3 A), the
Arg85-Asp476 paring (Fig. 3 B), the coordination information
of Na1 ions (Fig. 4, C and D and Table 1), and the key
distances fromdopamine to several closely contacted residues
and Na1 ions (Fig. 6). As shown in Fig. 3 A, during the ﬁrst
2 ns of the MD simulation, the Ca RMSD change of DAT-
dopamine complex was much smaller than that of the
corresponding DAT structure without dopamine. More
interestingly, Arg85 and Asp476 became a stable ion pair, as
tracked by the minimum distance between the charged side
chains of this pair of residues (Fig. 3 B), as the distance was
,3 A˚, at most, of the snapshots. These dynamic changes
reveal that the Na1-bound DATwas stabilized by the binding
of dopamine. In other words, the Na1-bound DAT can easily
accept dopamine as a substrate. After binding with dopamine,
the local intermolecular contacts became quite stable during
the MD simulation (Fig. 6 A), although the Ca RMSD
changes depicted in Fig. 3 A suggested a certain extent of
backbone motion for the complex structure.
The coordination of Na1 was perturbed by the binding of
dopamine. As listed in Table 1, Na1 kept Ala77 and Asn82 as
its ligands, and it lost the coordination from Phe76, Asn353,
and Ser357, while Asp79 and Phe320 became the new ligands
of Na1. Meanwhile, Ser321 also restored its role as a ligand
of Na1 (Fig. 4 C). It is worth noting that Asp79 switched its
role from coordinating Na2 through its side chain OD1 in
the DAT structure without dopamine to coordinating Na1
through its side chain OD2 in the DAT-dopamine complex.
This was the most remarkable change in the local binding
environment after the binding with dopamine, suggesting
an indispensable role of this charged residue in the process
of substrate-binding to DAT. Concerning the coordination of
Na2, after the dopamine binding to DAT, the OD1 atom
of Asp79 no longer coordinated to Na2 while its OD2 atom
coordinated the Na1. The coordination of Na2 from the OD1
of Asp79 in the DAT structure without dopamine was
FIGURE 5 Typical structure of the DAT-dopamine binding complex,
which was the 1.50 ns snapshot of the MD trajectory. (A) Viewing the
dopamine molecule (shown as ball-and-stick) in the complex model from the
extracellular side. Only part of the DAT is shown as ribbon in red, and Na2
as CPK in magenta. Helices 1, 6, 8, 10, and 12 are labeled to indicate the
relative position of dopamine in DAT. (B) Viewing the DAT in the binding
pocket in the same orientation as panel A. The binding pocket is represented
in molecular surface format, colored with electrostatic potentials in which
blue is for positive and red is for negative potentials.
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replaced by the backbone carbonyl oxygen of Val78 (Fig. 4 D)
in the simulated DAT-dopamine complex. Na2 kept its co-
ordination from Gly75, Leu418, and Asp421, but its coordi-
nation from Ser422 was lost. Another signiﬁcant change was
the coordination numbers of both Na1 ions after the
dopamine binding, i.e., from 6 in the DAT structure without
dopamine to 5 in the DAT-dopamine complex (Table 1). The
decreased coordination numbers of both Na1 ions can be
attributed to both the steric and electrostatic effects of the
positively charged dopamine. The MD-simulated average
distances from the cationic head of dopamine to Na1 and
Na2 (Fig. 6 B) were ;4.5 A˚ and ;5.5 A˚, respectively. On
the other hand, the repulsion between the positive charges
was neutralized by the negatively charged Asp79 and
partially by the surrounding helix dipoles.
The detailed atomic interactions between dopamine and
DAT are featured as electrostatic, hydrogen bonding, and
hydrophobic contacts, as shown in Fig. 7 for a typical struc-
ture of the MD-simulated complex at the 1.50 ns snapshot.
The hydrogen atoms on the positively charged head of
dopamine formed three hydrogen bonds with DAT. One
hydrogen bond was formed with the backbone carbonyl
oxygen of Phe76 from helix 1, the second was formed with the
side chain OD2 of Asp79 from helix 1, and the third with the
side-chain hydroxyl oxygen of Ser422 from helix 8. Mean-
while, the side-chain hydroxyl group of Ser422 had a hydrogen
bond with the side chain OD2 of Asp421. The distance from
the positively charged head of dopamine to the center of the
aromatic side chain of Phe76 was as short as 4.18 A˚. The
nearest hydrogen atom on the cationic head of dopamine had a
distance of 3.83 A˚ with the aromatic side chain of Phe76,
indicating a cation-p interaction. The role of Asp79 from helix
1 was twofold. The side chain OD2 of Asp79 coordinated to
Na1 and hydrogen-bonded to the cationic head of dopamine,
while its side chain OD1 hydrogen-bonded to the side-chain
hydroxyl group of Tyr156 from helix 3. The average distances
from the nitrogen atom of the positively charged head of
dopamine to the OD1 and OD2 atoms of Asp79 are within the
range of effective electrostatic interactions (2.79 A˚ and 4.16
A˚, respectively). The aromatic side chain of Tyr156 was in
close side packing with the aromatic ring of dopamine (Fig.
7). Such strong interactions between dopamine and the side
chains of Asp79, Tyr156, and Ser422 should be the major
binding forces anchoring dopamine to its binding site. Tyr156
is a strictly conserved residue between allmembers in theNSS
family (Fig. 1), and Ser422 is also conservative. Therefore, the
mutual interactions between the side chains of Tyr156 and
Asp79 may act as a latch to stabilize the irregular structure
around the unwound region of helix 1. The involvement of
Asp79 in the vital local interactions with both dopamine and
Na1 can explain why mutations Asp79Ala, Asp79Gly, and
Asp79Glu dramatically reduced dopamine reuptake as dem-
onstrated in previously reported experimental studies onDAT
FIGURE 6 (A) Distances from the atoms (the nitrogen and hydroxyl
oxygen atoms) of dopamine to the carbonyl oxygen of Phe76, side chain CG
of Asp79, Ca of Phe320, carbonyl oxygen of Ser422, and carbonyl oxygen of
Gly425. (B) Distances from the cationic head of dopamine to the bound Na1
ions as observed during the MD simulation of the DAT-dopamine complex.
FIGURE 7 Representative molecular interactions between dopamine and
DAT, taken at the 1.50-ns snapshot of the MD-simulated DAT-dopamine
complex. Residues from DAT within 5 A˚ of dopamine are labeled and
shown in stick style, while dopamine is shown in ball-and-stick. Critical
hydrogen-bonding interactions between dopamine and DAT are represented
as dash lines with labeled distances, also labeled the bound Na1 ions (Na1
and Na2).
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(18,19). The mode of electrostatic attraction plus hydrogen
bonding between Asp79 and the positively charged head of
dopamine is also supported by a recent mutational study on
the Asp79Glu mutant of DAT (24). The corresponding
position of Tyr156 in other members of the NSS family has
also been indicated in the substrate binding and translocation,
such as in serotonin transporter and g-aminobutyric acid
transporter (65–67). The substrate binding was not investi-
gated in the previous modeling studies on DAT (35,36).
In addition, the hydroxyl groups of dopamine formed two
hydrogen bonds with DAT, one with the backbone carbonyl
oxygen of Ser422 and the other with the backbone carbonyl
oxygen of Gly425 from helix 8. These two hydrogen bonds
helped to orient the aromatic ring of dopamine in better
parallel packing with the aromatic side chain of Phe326 from
helix 6. Additional hydrophobic contacts between dopamine
and DAT came from the hydrophobic side chains of several
other residues. Side chains of Ala77, Ala81, and Phe320 interact
with the alkyl chain of dopamine between its cationic head
and aromatic ring. Gly426 and side chains of Val152 andVal328
added more contacts with the aromatic ring of dopamine.
As observed from the MD simulation, Phe76, Asp79,
Ser422, and Gly425 had strong hydrogen-bonding interactions
with the cationic head and hydroxyl groups of dopamine
(Table 2). The total fraction of hydrogen bonding for each of
these residues is always over 0.95 during the 2.476 ns MD
simulation.
Comparison with available site-directed
mutagenesis studies
Our modeled structures of DAT and its binding with
dopamine can be used to understand the experimental results
obtained from previously reported site-directed mutagenesis
studies (18,19,22,28). As discussed above, according to our
DATmodel, the negatively charged atoms at the side chain of
Asp79 interact with the cationic head of dopamine through the
direct hydrogen-bonding and electrostatic interactions. Mu-
tations on this residues, such as Asp79Ala and Asp79Gly, are
expected to abolish these crucial interactions, and thus these
mutations lead to the loss of the dopamine-reuptake function
as reported by Uhl et al. (18). Asp79Glu mutation is also
expected to signiﬁcantly weaken its interactions with the
cationic head of dopamine and the two Na1 ions, which
explains why this mutation also dramatically reduced the do-
pamine reuptake (18). As reported also by Uhl et al. (19),
Phe155Ala mutation caused only 3% decrease in the binding
afﬁnity of dopamine. According to our model of DAT in
complex with dopamine, Phe155 is located just above the do-
pamine binding pocket, and the shortest internuclear distance
between Phe155 and dopamine is .5 A˚. The possible hydro-
phobic interaction between Phe155 with dopamine should be
very weak, making this residue much less important than
other residues inside the dopamine-binding pocket.
It has been known that Asp313Asn mutation decreased the
Km for dopamine binding with DAT by sixfold (22), whereas
Lys257A and Arg283Ala mutations increased the Km for do-
pamine binding with DAT by sixfold and threefold, respec-
tively (28). Based on our modeled structures, the distance
between the negatively charged atoms of Asp313 side chain
and the cationic head of dopamine is ;8 A˚, whereas the
distances from the cationic head of dopamine to the positively
charged atoms of Lys257 and Arg283 side chains are ;10 A˚
and ;11 A˚, respectively. In consideration of the long-range
electrostatic interactions between the charged dopamine and
these charged residues, with the Asp313Asn mutation, the net
TABLE 2 The hydrogen-bonding (HB) interactions between DAT and dopamine in the MD-simulated DAT-dopamine complex
Residue Donor Acceptor Residue HBdist (A˚) (SD) Fraction
DA N1-H3 O¼C Phe76 2.796 (0.11) 0.731
DA N1-H5 O¼C Phe76 2.794 (0.10) 0.258
DA N1-H5 OD2 Asp79 2.839 (0.12) 0.732
DA N1-H4 OD2 Asp79 2.850 (0.13)) 0.253
DA N1-H4 OG Ser422 2.987 (0.15) 0.618
DA N1-H3 OG Ser422 2.976 (0.17) 0.211
DA O1-H10 O¼C Ser422 2.672 (0.11) 0.979
DA O1-H10 O¼C Gly425 2.360 (0.15)) 0.024
DA O2-H11 O¼C Gly425 2.745 (0.14) 0.953
The criteria/cutoffs used for the HB counting was 3.5 A˚ for the distance (HBdist) between the donor and acceptor atoms and 110 for the HB angle along the
donor, hydrogen, and the acceptor. The HB fraction was calculated as the ratio of the number of snapshots with the HB to the number of total snapshots
collected. All HB pairs with fractions over 1% and their average HBdist values are listed with the standard deviations (SD) in parentheses. See scheme below.
.
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charge of the residue changes from1 to 0 and, therefore, the
favorable electrostatic attraction between Asp313 and dopa-
mine is expected to vanish. With the Lys257 or Arg283 muta-
tion, the net charge of the residue changes from11 to 0 and,
therefore, the unfavorable electrostatic repulsion between the
residues and dopamine is expected to disappear. These results
qualitatively explain why the Asp313Asn mutation decreased
the Km for dopamine binding with DAT (22), whereas
Lys257A and Arg283Ala mutations increased the Km for
dopamine binding with DAT (28).
As observed in previously reported experimental studies,
the Trp84Leu mutation on helix 1 and the Leu104Val,
Phe105Cys, and Ala109Val mutations on helix 2 had no
obvious effects on the Km value for dopamine binding with
DAT (22,25,26). This is because these residues are far away
from the dopamine-binding site according to our modeled
structures. In addition, based on our modeled structures and
the MD simulations trajectory, amino-acid residues His375 to
Ile379 at the extracellular end of helix 7 belong to a loop and
residue Glu396 is at the beginning of helix 8. Such a structural
feature is also consistent with the key distances determined in
a study of the structure-function relationship by performing
the Zn21-site engineering (20).
Binding free energy
In the MM-PBSA calculation of the binding free energy for
the DAT-dopamine binding using the modeled structure
before the MD simulation, we obtained DEbind ¼ –21.6 kcal/
mol and –TDS ¼ 16.0 kcal/mol at T ¼ 298.15 K. Thus, the
binding free energy (DGbind) between dopamine and DAT
was calculated to be –5.6 kcal/mol by using the DAT
structure before the MD simulation. Based on the calculated
DGbind value, the dissociation constant (Kd) for the DAT-
dopamine complex is estimated to be 7.8 3 105 M (or 78
mM). We also calculated the binding free energy by using the
MD-simulated DAT-dopamine structure. The MM-PBSA
calculations were performed on 120 snapshots (i.e., one
snapshot per 10 ps) taken from the last 1.2 ns of the MD
trajectory (see Fig. 3 A). For each of these 120 snapshot
structures, we carried out the calculations on both the gas-
phase binding energy and the solvent shift. The ﬁnal results
were taken as the averages of the corresponding energetic
values calculated with the 120 snapshots. Based on the
calculated results, the binding energy shift due to the MD
simulation was determined to be –0.8 kcal/mol, i.e., DGbind
(after MD) ¼ –5.6  0.8 ¼ 6.4 kcal/mol. Based on the
DGbind value of –6.4 kcal/mol, the dissociation constant (Kd)
is evaluated to be 20 mM, which is closer to the experimental
DGbind value of –7.4 kcal/mol derived from the experimental
KM value of 3.466 6 0.200 mM (28). The deviation (;1.0
kcal/mol) of the calculated binding afﬁnity from the ex-
perimental value may be attributed to the approximations
inherent in MM-PBSA method (51). For example, explicit
solvent molecules were employed in the optimization and
MD simulations of the DAT-dopamine complex model, but
were subsequently replaced with a continuum solvent model
in the calculation of the solvation free energy contribution
(DGsolv) through solving the PB equation (52,53). A recently
reported computational study (68) also demonstrated that the
MM-PBSA method could signiﬁcantly underestimate the
binding free energy.
Substrate-entry pathway
Based on the MD-simulated DAT-dopamine complex struc-
ture, a top view on the dopamine binding site from the
extracellular side shows that dopamine was positioned inside
a hydrophobic pocket (Fig. 5). The cradlelike pocket was
covered by the aromatic side chains of Phe320 and Phe326 and
the hydrophobic side chain of Val152 (Figs. 7 and 8). This top
cover of the binding pocket was further stacked by the side
chains of Phe155 from helix 3, Arg85 from helix 1, and Asp476
from helix 10. Although the charged side-chain atoms of
residues Arg85 and Asp476 were seldomly in direct charge-
charge interactions, as indicated in the MD simulation on
FIGURE 8 Side view of the proposed dopamine-entry pathway in DAT
with TM12 parallel to the normal of the membrane. The protein is shown as
ribbon with helix 1 in green, helix 3 in cyan, helix 6 in blue, helix 8 in
magenta, and other helices in red. With helices 3 and 8 in front, the back wall
of the pathway is represented by molecular surface in gray, and residues
220–241 are not shown for clear view of the pathway back wall. The relative
position of the membrane bilayer is indicated. The proposed substrate-entry
pathway starts from the extracellular side as indicated by the large green
arrow, going down inside the tunnel along the dashed green arrow to the
binding pocket. The side chains of residues on the way of the tunnel to the
binding pocket are shown in stick representation and labeled in blue. These
are the salt-bridge pair of Arg85 and Asp476, aromatic residues as Phe155,
Ty156, Phe320, and Phe326. Dopamine is labeled as DA and the second Na1
as Na2 in blue.
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DAT (black curve in Fig. 3 B), the mutual interactions
between these two residues were probably mediated by the
surrounding solvent water molecules. These two charged
residues were just over the top of Phe326 from helix 6. The
NH groups of Arg85 side chain also formed a hydrogen bond
with the carbonyl oxygen on the side chain of Gln317 from
helix 6. Except these intramolecular interactions, the funnel-
like tunnel formed by the helices 1, 3, 6, 8, and 10 was quite
opening toward the extracellular side of the membrane
bilayer (Fig. 7).
Considering the unwinding features of helices 1 and 6
around the midpoint of the membrane, it is not difﬁcult for the
up-half of helices 1 and 6 to move apart or toward each other
by using the unwound regions of these two helices as the joint
points. Such unique ﬂexibility of the substrate-binding do-
main of DAT affords a possible, reasonable pathway for the
entry of Na1 ions and substrate dopamine toward their
binding sites. That is, once captured near the mouth in the
extracellular side of DAT, dopaminemolecule can slide down
to the door of binding pocket (dashed green arrow in Fig. 8).
By the help of electrostatic attraction from Asp476, the en-
tering of dopamine probably brings about local motion of the
up-half of helices 1 and 6. After further sliding of dopamine
molecule toward the binding pocket, the charged atoms of
Arg85 and Asp476 come closer to each other. In coupling with
the dopamine molecule orientating in the binding pocket, the
coordinations of both Na1 ions are adjusted. As a balance, the
Arg85-Asp476 salt bridge is formed (Fig. 3 B), thus stabilizing
the whole complex structure (Figs. 6 and 7).
CONCLUSION
This computational modeling, molecular docking, and mo-
lecular dynamics simulations have led us to develop a
reasonable three-dimensional (3D) structural model of dopa-
mine transporter (DAT) and its binding dopamine. Our
modeled 3D structures of DAT and its complex with dopa-
mine have provided some detailed structural and mechanistic
insights concerning how DAT interacts with its substrates at
atomic level, extending our mechanistic understanding of
DATmodulating the dopamine reuptake with the help of Na1
ions. The general features of our modeled 3D structures are
consistent with all of the available experimental data. Based
on the modeled 3D structures, our calculated binding free
energy for dopamine binding with DAT is also reasonably
close to the experimentally measured binding afﬁnity.
Finally, a possible substrate-entry pathway, which involves
the formation and breaking of the Arg85-Asp476 salt bridge, is
proposed according to the results obtained from the modeling
and MD simulation. The new structural and mechanistic
insights obtained from this computational study should be
valuable for design of future, further biochemical and phar-
macological studies on the detailed structures and mecha-
nisms of DAT and other homologous members of the
neurotransmitter sodium symporters (NSS) family.
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